Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

LAPRYSTA 10 MG/ML JARABE EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/LAPRYSTA 10 MG/ML JARABE EFG

Approved

STANDARD

LAPRYSTA 10 MG/ML JARABE EFG

Neuraxpharm Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 19, 2022
Approval ID: e9be5e75ba5c5b3a
Company: Neuraxpharm Spain S.L.
Type: Standard

Approval Details

Approval Id: e9be5e75ba5c5b3a
Drug Cima Aemps Name: LAPRYSTA 10 MG/ML JARABE EFG
Register Number: 87322
Holder Company Name: Neuraxpharm Spain S.L.
Marketing Company Name: Neuraxpharm Spain S.L.
Authorization Date: 2022-05-19
Dosage Form: JARABE
Dose: 10 mg/ml
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Neuraxpharm Spain S.L.

Active Ingredients

LACOSAMIDA

10 mg/ml

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 19, 2022

Approval ID

e9be5e75ba5c5b3a

Type

Standard

Back to CIMA-AEMPS Approvals